InsidersTradesSigma
COLLEGIUM PHARMACEUTICAL, INC Stock: price and management transactions · United States · SEC (Form 4)
Follow the COLLEGIUM PHARMACEUTICAL, INC share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares trade on US US, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, COLLEGIUM PHARMACEUTICAL, INC has recorded 151 insider filings. Market capitalisation: €1.2bn. The latest transaction was filed on 15 May 2026 (Cession). Among the most active insiders: Ciaffoni Joseph. The full history is accessible without an account.
151
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
€11m
42 ops.
Sell Volume
44Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 1,618 of 25,804 companies
77.5
score / 100
Value84
Quality71
FCF yld28%
Earn yld5.3%
EV/EBITDA5.0x
ROE27%
Gross mgn59%
Net mgn8.1%
Debt/EBITDA2.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 15 May 2026
Declarations151 total
4,500 shares@ US$35.96910.0094% mcap50.0% of flowCommon StockSEC:0001450485-26-000007:0
4,500 shares@ US$35.96910.013% mcap50.0% of flowCommon StockSEC:0001450485-26-000007
8,700 shares@ US$16.490.0083% mcap100.0% of flowCommon StockSEC:0001254705-26-000002:0
3,650 shares@ US$47.0338100.0% of flowCommon StockSEC:0001825625-25-000004:0
9,791 shares0Common StockSEC:0001062993-25-009809:0
9,791 shares0Common StockSEC:0001062993-25-009810:0
9,791 shares0Common StockSEC:0001062993-25-009806:0
9,791 shares0Common StockSEC:0001062993-25-009807:0
9,791 shares0Common StockSEC:0001062993-25-009805:0
9,791 shares0Common StockSEC:0001062993-25-009808:0
19,582 shares0Common StockSEC:0001062993-25-009804:0
1,927 shares@ US$30.00051.2% of flowCommon StockSEC:0001062993-25-006148:0
1,206 shares@ US$30.00111.8% of flowCommon StockSEC:0001062993-25-006149:0
68,449 shares0Common StockSEC:0001062993-25-005904:0
15,387 shares@ US$30.00410.0% of flowCommon StockSEC:0001062993-25-005834:0
2,255 shares@ US$30.00491.5% of flowCommon StockSEC:0001062993-25-005752:0
977 shares@ US$30.00341.5% of flowCommon StockSEC:0001062993-25-005753:0
10,445 shares@ US$30.00616.0% of flowCommon StockSEC:0001062993-25-005395:0
15,387 shares@ US$30.00410.1% of flowCommon StockSEC:0001062993-25-005396:0
1,949 shares@ US$30.003.0% of flowCommon StockSEC:0001062993-25-005021:0
3,295 shares@ US$30.00112.2% of flowCommon StockSEC:0001062993-25-005020:0
40,000 shares@ US$24.0321.0% of flowCommon StockSEC:0001062993-25-004776:0
45,016 shares0Common StockSEC:0001062993-25-002179:0
33,762 shares0Common StockSEC:0001062993-25-002180:0
4,820 shares0Common StockSEC:0001062993-25-002181:0
25 of 151 declarations
About COLLEGIUM PHARMACEUTICAL, INC
Collegium Pharmaceutical, Inc. is a U.S.-listed biopharmaceutical company trading on the NASDAQ under the ticker COLL. Its headquarters are in Stoughton, Massachusetts, United States. Collegium is best described as a specialty pharma company with a focused commercial model built around differentiated prescription medicines rather than broad early-stage discovery. Founded in the early 2000s, the company has evolved through a combination of in-house development, portfolio expansion, and targeted acquisitions. Collegium’s historical core has been pain management, an area that remains highly regulated and commercially specialized. Its key products include Xtampza ER, an abuse-deterrent extended-release oxycodone formulation built on proprietary technology; Belbuca, a buprenorphine buccal film for severe chronic pain; and the Nucynta franchise, which includes tapentadol products for immediate- and extended-release use. More recently, the company has added a meaningful ADHD growth platform through Jornay PM, a delayed-release/extended-release methylphenidate product designed for evening dosing. That portfolio mix gives Collegium a more balanced revenue base than a pure single-asset story, although the company still remains concentrated in a relatively small number of commercial brands. From a competitive standpoint, Collegium occupies a niche position versus larger diversified pharmaceutical peers. Its strengths lie in formulation science, controlled-substance commercialization, payer/access execution, and a specialized sales model focused on prescribers in pain and, increasingly, attention disorders. In pain, Collegium competes with much larger branded and generic players, but its products are differentiated by dosage form, abuse-deterrence features, and patient use case. This can support resilience in specific segments, but it also leaves the business exposed to prescription trends, regulatory scrutiny, pricing pressure, and portfolio concentration risk. Recent company developments have been notable. In 2025 and early 2026, Collegium reported continued revenue growth, strong performance from Jornay PM, and solid contributions from its pain portfolio. The company also closed a $980 million syndicated credit facility, signaling active capital structure management. Another major strategic step came in March 2026, when Collegium announced the acquisition of AZSTARYS from Corium Therapeutics, strengthening its ADHD presence and extending its growth runway. Collegium has also continued to work on commercial partnerships, including arrangements related to authorized generics for the Nucynta franchise. For investors, COLL is a NASDAQ-listed United States healthcare name with a specialty-pharma profile, combining mature franchise durability with selective growth opportunities in pain and ADHD.
